1134. Lenzilumab Treatment in COVID-19 Pneumonia Reduces Circulating Cytokines and Markers of Systemic Inflammation

por Chappell, Dale, Kilcoyne, Adrian, Cerasoli, Frank, Lukas, John, Durrant, Cameron, Temesgen, Zelalem, Polk, Christopher, Baker, Jason, Marconi, Vincent
Publicado 2022

P737: LENZILUMAB AND AZACITIDINE IMPROVE HEMATOLOGIC ALTERATIONS OF CHRONIC MYELOMONOCYTIC LEUKEMIA IN THE PREACH-M TRIAL

por Ross, David, Hiwase, Devendra, Lane, Steven, Sharplin, Kirsty, Yong, Agnes, David, Yeung, Chappell, Dale, Durrant, Cameron, Hughes, Timothy, Thomas, Daniel
Publicado 2023

Clinical and Economic Benefits of Lenzilumab Plus Standard of Care Compared with Standard of Care Alone for the Treatment of Hospitalized Patients with Coronavirus Disease 19 (COVI...

por Kilcoyne, Adrian, Jordan, Edward, Thomas, Kimberly, Pepper, Alicia N, Zhou, Allen, Chappell, Dale, Amarapala, Miyuru, Thériault, Rachel-Karson, Thompson, Melissa
Publicado 2022

C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 ‘LIVE-AIR’ trial

por Temesgen, Zelalem, Kelley, Colleen F, Cerasoli, Frank, Kilcoyne, Adrian, Chappell, Dale, Durrant, Cameron, Ahmed, Omar, Chappell, Gabrielle, Catterson, Victoria, Polk, Christopher, Badley, Andrew, Marconi, Vincent C
Publicado 2023

LENZILUMAB EFFICACY AND SAFETY IN NEWLY HOSPITALIZED COVID-19 SUBJECTS: RESULTS FROM THE LIVE-AIR PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL

por Temesgen, Zelalem, Burger, Charles D., Baker, Jason, Polk, Christopher, Libertin, Claudia, Kelley, Colleen, Marconi, Vincent C., Orenstein, Robert, Durrant, Cameron, Chappell, Dale, Ahmed, Omar, Chappell, Gabrielle, Badley, Andrew D.
Publicado 2021

C-REACTIVE PROTEIN AS A BIOMARKER FOR IMPROVED EFFICACY OF LENZILUMAB IN PATIENTS WITH COVID-19: RESULTS FROM THE LIVE-AIR TRIAL

por TEMESGEN, ZELALEM, BURGER, CHARLES, BAKER, JASON, POLK, CHRISTOPHER, LIBERTIN, CLAUDIA, KELLEY, COLLEEN, MARCONI, VINCENT, ORENSTEIN, ROBERT, CATTERSON, VICTORIA, ARONSTEIN, WILLIAM, DURRANT, CAMERON, CHAPPELL, DALE, CHAPPELL, GABRIELLE, AHMED, OMAR, BADLEY, ANDREW
Publicado 2021

40. Lenzilumab Efficacy and Safety in Newly Hospitalized COVID-19 Subjects: Results From a Phase 3 Randomized Double-Blind Placebo-Controlled Trial

por Temesgem, Zelalem, Burger, Charles, Baker, Jason, Polk, Christopher, Libertin, Claudia R, Kelley, Colleen F, Marconi, Vincent, Orenstein, Robert, Catterson, Victoria, Aronstein, William, Durrant, Cameron, Chappell, Dale, Ahmed, Omar, Chappell, Gabrielle, Badley, Andrew
Publicado 2021

Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial

por Temesgen, Zelalem, Burger, Charles D, Baker, Jason, Polk, Christopher, Libertin, Claudia R, Kelley, Colleen F, Marconi, Vincent C, Orenstein, Robert, Catterson, Victoria M, Aronstein, William S, Durrant, Cameron, Chappell, Dale, Ahmed, Omar, Chappell, Gabrielle, Badley, Andrew D
Publicado 2022

GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study

por Temesgen, Zelalem, Assi, Mariam, Shweta, F.N.U., Vergidis, Paschalis, Rizza, Stacey A., Bauer, Philippe R., Pickering, Brian W., Razonable, Raymund R., Libertin, Claudia R., Burger, Charles D., Orenstein, Robert, Vargas, Hugo E., Palraj, Raj, Dababneh, Ala S., Chappell, Gabrielle, Chappell, Dale, Ahmed, Omar, Sakemura, Reona, Durrant, Cameron, Kenderian, Saad S., Badley, Andrew D.
Publicado 2020

GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity

por Cox, Michelle J., Roman, Claudia Manriquez, Tapper, Erin E., Siegler, Elizabeth L., Chappell, Dale, Durrant, Cameron, Ahmed, Omar, Sinha, Sutapa, Mwangi, Raphael, Scott, Nancy S., Hefazi, Mehrdad, Schick, Kendall J., Horvei, Paulina, Ruff, Michael W., Can, Ismail, Adada, Mohamad, Bezerra, Evandro, Fonkoua, Lionel Aurelien Kankeu, Parikh, Sameer A., Kay, Neil E., Sakemura, Reona, Kenderian, Saad S.
Publicado 2022